HDAC9 and Alzheimer disease: Based on their findings, Noh et al. [118] evaluated VPA treatment in a Tg6779 murine AD model and found that VPA reduced the levels of neuroinflammatory cytokines at late symptomatic stages of AD by the inhibition of HDAC.